Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.

ABSTRACT:

Objective

We examined a cohort of Australian patients with statin exposure who developed a necrotizing autoimmune myopathy (NAM) associated with a novel autoantibody against 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and describe the clinical and therapeutic challenges of managing these patients and an optimal therapeutic strategy.

Methods

Clinical, laboratory, EMG, and histopathologic results and response to immunomodulation are reported in 6 Australian patients with previous statin exposure and antibodies targeting HMGCR.

Results

All patients presented with painless proximal weakness following statin therapy, which persisted after statin cessation. Serum creatine kinase (CK) levels ranged from 2,700 to 16,200 IU/L. EMG was consistent with a myopathic pi

SUBMITTER: Ramanathan S 

PROVIDER: S-EPMC4386794 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature